Keytruda/Lenvima combo shows promise in hard-to-treat cancers
Data shows a range of responses in different tumours
Read More
Author: Lucy Parsons
Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer
Detailed results presented at ESMO also show benefit in prostate cancer
Read More
University of Edinburgh spinout Cellinta will develop gene therapies for cancer
Investors include SV Health Investors and Cancer Research UK
Read More
CHMP backs seven new meds in September meeting
Positive opinions include Pacira’s Exparel and two new vaccines from Sanofi
Read More
Bayer’s Vitrakvi shows long-term efficacy in TRK fusion-positive cancers
Tumour agnostic therapy demonstrates sustained efficacy
Read More- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
